Immunomedics, Inc. (IMMU) EPS Estimated At $-0.10

January 13, 2018 - By Stephen Andrade

 Immunomedics, Inc. (IMMU) EPS Estimated At $ 0.10
Investors sentiment increased to 1.65 in Q3 2017. Its up 0.24, from 1.41 in 2017Q2. It improved, as 16 investors sold Immunomedics, Inc. shares while 36 reduced holdings. 38 funds opened positions while 48 raised stakes. 111.69 million shares or 33.14% more from 83.89 million shares in 2017Q2 were reported.
Jane Street Ltd reported 0% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). Axa, France-based fund reported 33,000 shares. Lpl Financial, California-based fund reported 13,073 shares. Wellington Management Group Inc Llp reported 151,347 shares. Zurcher Kantonalbank (Zurich Cantonalbank) stated it has 0% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). Suntrust Banks holds 28,400 shares. Venbio Select Advisor Ltd Liability Co holds 14.74 million shares or 15.98% of its portfolio. Knott David M, a New York-based fund reported 65,483 shares. Opaleye Mngmt Inc holds 898,800 shares or 4.44% of its portfolio. Millennium Limited Liability, New York-based fund reported 2.90M shares. Art Advsr Limited Liability holds 0.09% or 122,500 shares in its portfolio. Barclays Public Limited Liability Company reported 0% stake. Voya Invest Mngmt Lc accumulated 50,433 shares or 0% of the stock. Citadel Advsrs Limited Liability Corporation owns 1.16 million shares. Moreover, Deutsche Natl Bank Ag has 0.01% invested in Immunomedics, Inc. (NASDAQ:IMMU) for 1.39 million shares.

Since August 21, 2017, it had 0 insider purchases, and 6 sales for $2.10 million activity. 20,000 shares were sold by GOLDENBERG CYNTHIA L, worth $252,750.

Analysts expect Immunomedics, Inc. (NASDAQ:IMMU) to report $-0.10 EPS on February, 8.They anticipate $0.06 EPS change or 37.50 % from last quarter’s $-0.16 EPS. After having $-0.16 EPS previously, Immunomedics, Inc.’s analysts see -37.50 % EPS growth. The stock increased 1.60% or $0.26 during the last trading session, reaching $16.51. About 2.27 million shares traded. Immunomedics, Inc. (NASDAQ:IMMU) has risen 76.26% since January 13, 2017 and is uptrending. It has outperformed by 59.56% the S&P500.

Immunomedics, Inc. (NASDAQ:IMMU) Ratings Coverage

Among 3 analysts covering Immunomedics (NASDAQ:IMMU), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Immunomedics had 15 analyst reports since July 29, 2015 according to SRatingsIntel. Jefferies maintained it with “Buy” rating and $16 target in Monday, October 9 report. Jefferies maintained Immunomedics, Inc. (NASDAQ:IMMU) on Tuesday, March 15 with “Hold” rating. Cowen & Co maintained Immunomedics, Inc. (NASDAQ:IMMU) on Wednesday, August 16 with “Buy” rating. Jefferies downgraded the stock to “Hold” rating in Wednesday, July 29 report. The firm has “Buy” rating by Jefferies given on Friday, June 9. Jefferies maintained Immunomedics, Inc. (NASDAQ:IMMU) rating on Tuesday, September 19. Jefferies has “Buy” rating and $14.0 target. The stock of Immunomedics, Inc. (NASDAQ:IMMU) has “Buy” rating given on Thursday, August 17 by Jefferies. The firm has “Market Perform” rating by Wells Fargo given on Friday, December 4. The rating was reinitiated by Jefferies with “Buy” on Thursday, October 6. Cowen & Co maintained it with “Buy” rating and $15.0 target in Wednesday, December 6 report.

Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company has market cap of $2.65 billion. The firm engages in developing antibody-drug conjugate products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers. It currently has negative earnings. It also develops products for the treatment of cancer and autoimmune diseases, including epratuzumab, anti-CD22 antibody; veltuzumab, anti-CD20 antibody; milatuzumab, anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: